Zobrazeno 1 - 10
of 79
pro vyhledávání: ''
Autor:
A. Virtuoso, Carlo Signorelli, F. Primi, M.G. Chilelli, A. Fabbri, Enzo Maria Ruggeri, J.R. Giron Berrios, A. Onorato, Diana Giannarelli, M. Mazzotta, M.A. Silvestri, E. Marrucci, Fabrizio Nelli, M. Schirripa
Publikováno v:
Annals of Oncology
Autor:
G. Antonarelli, Liliana Ascione, Giuseppe Curigliano, Javier Cortes, Mary L. Disis, Elizabeth A. Mittendorf, Paolo Tarantino, Chiara Corti, Pedro Romero
Publikováno v:
Annals of Oncology
Cancer vaccines (CVs) represent a long-sought therapeutic and prophylactic immunotherapy strategy to obtain antigen (Ag)-specific T-cell responses and potentially achieve long-term clinical benefit. However, historically, most CV clinical trials have
Publikováno v:
Annals of Oncology
Autor:
Enrique Gallardo, A. González del Alba, J.J. Soto, S. Pérez, M.A. Climent Duran, I. Martinez Salas, A. Martín, Montserrat Domenech, E. Almagro Casado, M.A. Cuellar, N. Vidal, M. Martinez Kareaga, Sergio Vazquez, Georgia Anguera, Javier Puente, Alejo Rodriguez-Vida, N. Diaz-Mejía, M.J. Méndez-Vidal, J.C. Villa Guzman, O. Fernandez Calvo
Publikováno v:
Annals of Oncology
Autor:
M. Abuladze, Nino Balanchivadze, N. Jokhadze, T. Esakia, S. Tsitsilashvili, N. Otkhozoria, T. Melkadze, E. Mariamidze, K Tsiklauri
Publikováno v:
Annals of Oncology
Background: COVID-19 pandemic created major challenges in cancer care. Studies have shown increased risk for COVID-19 infectivity, severe disease and death in patients with cancer. Cancer centers worldwide adapted by modifying and often delaying trea
Publikováno v:
Annals of Oncology
Background: In the COVID-19 era, a simplified risk assessment algorithm for CIN might optimize resource utilization. Since Gr4N toxicity is frequently measured and reported in clinical trial results, Gr4N frequency might predict adverse clinical outc
Autor:
Rachel Würstlein, Fabian Trillsch, Tom Degenhardt, M Forster, Alexander Burges, Sven Mahner, Nadia Harbeck, A König, A. Chelariu-Raicu, S Beyer
Publikováno v:
Annals of Oncology
Background: Cancer patients are at increased risk of developing severe COVID-19 disease. Possible side effects of systemic therapy and the lack of clinical data on safety and efficacy of COVID-19 vaccination in cancer patients cause uncertainty regar
Autor:
C. Royo-Cebrecos, J. Serrano Pons, E. Baillés, J. Pujadas olano, D. Vilanova, S. Albiol Rodriguez, I. Ambatlle, E. Mahia, Francesc Cobo, Ï. Robert, J.M. Buldon
Publikováno v:
Annals of Oncology
Europe PubMed Central
Europe PubMed Central
Background: Little is known about the duration of SARS-CoV-2 antibodies and the factors that influence their durability in oncologic patients. This study aims to study serological response over time by means of a follow-up period of 6, 9 and 12 month
Autor:
H. Boussen, Nouha Daoud, H. Rachdi, Soumaya Laabidi, M. Nesrine, I. Ben Abdallah, Y. Berrazega
Publikováno v:
Annals of Oncology
Background: The COVID-19 pandemic was confirmed to have reached Tunisia on March 2nd, 2020, and has therefore disrupted oncology practice ever since. We report the main difficulties encountered by oncologists across the country during the pandemic. M
Autor:
Narimã Marques, James Glasbey
Publikováno v:
Annals of Oncology
Background: Surgery is the main modality of cure for solid cancers and was prioritised to continue even during SARS-CoV-2 outbreaks. This study aimed to identify immediate areas for system strengthening by comparing the delivery of elective cancer su